Innovative reward mechanism

A Case Study Using Claims Data from the Netherlands

Sahar Barjesteh van Waalwijk van Doorn-Khosrovani (PharmD-PhD)

CZ Health Insurance & National Funder's Committee for Evaluation of Specialised Medicines and Companion Diagnostics, the Netherlands

Department of Medical Oncology, Leiden University Medical Centre, the Netherlands

Authorised indications in Resected Stage III or IV melanoma

EORTC 1325 / KEYNOTE-054
and CheckMate-238



1 year of adjuvant therapy

Continuous decline in the number of patients receiving adjuvant therapy based on the label



*The 2025 claim data were not yet complete

The NEW ENGLAND JOURNAL of MEDICINE

CURRENT ISSUE SPECIALTIES TOPICS

ORIGINAL ARTICLE

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Authors: Sapna P. Patel, M.D., Megan Othus, Ph.D., Yuanbin Chen, M.D., Ph.D., G. Paul Wright, Jr., M.D., Kathleen J. Yost, M.D., John R. Hyngstrom, M.D., Siwen Hu-Lieskovan, M.D., Ph.D., +45, and Antoni Ribas, M.D., Ph.D. Author Info & Affiliations

Published March 1, 2023 | N Engl J Med 2023;388:813-823 | DOI: 10.1056/NEJMoa2211437 | VOL. 388 NO. 9

Funded by the National Cancer Institute and Merck Sharp and Dohme

3 doses of neoadjuvant

15 doses of adjuvant

SWOG S1808



The NEW ENGLAND JOURNAL of MEDICINE

CURRENT ISSUE SPECIALTIES TOPIC

ORIGINAL ARTICLE

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

Authors: Christian U. Blank, M.D., Ph.D., Minke W. Lucas, M.D. , Richard A. Scolyer, M.D. , Bart A. van de Wiel, M.D., Ph.D., Alexander M. Menzies, M.D., Ph.D., Marta Lopez-Yurda, Ph.D., Lotte L. Hoeijmakers, M.D., +60 , and Georgina V. Long, M.D., Ph.D. Author Info & Affiliations

Published June 2, 2024 | N Engl J Med 2024;391:1696-1708 | DOI: 10.1056/NEJMoa2402604

Funded by Bristol Myers Squibb and others

NADINA trial

2 cycles of nivolumab +Ipilimumab



Major Pathological Response?

No additional therapy

12 cycles of adjuvant Nivo



HR (95% CI)	Log Rank P-value
0.40 (0.28-0.57)	<0.001
0.67 (0.42-0.94)	0.02



*The 2025 claim data were not yet complete

Summary

Post-Marketing dose-optimisation studies could lead to a competitive advantage

- ✓ Resource-saving schemes are encouraged by hospitals and payers
- ✓ An improved efficacy and safety profile results in stronger clinician trust